Bexagliflozin Efficacy and Safety Trial

Summary

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The data from this study will be combined with the data from other bexagliflozin studies in a meta-analysis of CV safety outcomes.

Timeline

Start

2015-10

Primary completion

2018-08

Completion

2019-10-23

Drugs

Indications